Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

US to Lose Dominance of Global Generics Market as Emerging Economies Take Over

By GBI Research | October 5, 2016

Although the US is currently the largest generic drugs market by revenue globally, this is expected to change gradually, and dominance will soon shift to emerging markets including India, China, and Brazil, according to a survey from business intelligence provider GBI Research.

The company’s latest report states that, according to an extensive survey of 47 generic drugs industry experts conducted by GBI Research, 29% believed that China would become the highest revenue-generating emerging market for generic drug manufacturers in the next five years. This was followed closely by India at 23% of respondents. 

Deekshita Allavarapu, Analyst for GBI Research, states: “Although the US is currently dominating the generics market, emerging markets have been the most important geographical growth drivers for generics in the recent past. For example, Indian pharmaceutical companies are already well positioned in this industry, with their advanced technological capabilities and low-cost manufacturing.

“Despite emerging economies having relatively lower healthcare spending than developed economies, their healthcare costs are expected to significantly rise in the near future, driven by the adoption or expansion of universal healthcare and a growing incidence of lifestyle diseases.

“In countries such as China, obesity and diabetes are on the rise and disposable incomes are increasing through the expansion of the middle classes. In this way, the adoption of generic drugs is very likely to be seen as a strategy to control costs, given the potential savings these types of drugs can represent.”

Overall, GBI Research believes the generics market is dynamic and will continue to grow faster with continued demand for pharmaceuticals and efforts to lower healthcare costs. Due to the anticipated high adoption of generics in emerging economies, generic drug companies have started to more aggressively target these countries including Brazil, Russia, India, China, Mexico, Indonesia, Nigeria, and Turkey, as these markets are expected to exhibit significant increases in generics production.

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news! 


Filed Under: Drug Discovery

 

Related Articles Read More >

Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
Labcorp widens precision oncology toolkit, aims to speed drug-trial enrollment
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE